Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
- Published In:
- Lancet (London, England), 399(10343), 2267-2279 (2022)
- Authors:
- Giudice, Linda C, As-Sanie, Sawsan, Arjona Ferreira, Juan C, Becker, Christian M, Abrao, Mauricio S, Lessey, Bruce A, Brown, Eric, Dynowski, Krzysztof, Wilk, Krzysztof, Li, Yulan, Mathur, Vandana, Warsi, Qurratul Ann, Wagman, Rachel B, Johnson, Neil P
- Database ID:
- RPEP-06142
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06142APA
Giudice, Linda C; As-Sanie, Sawsan; Arjona Ferreira, Juan C; Becker, Christian M; Abrao, Mauricio S; Lessey, Bruce A; Brown, Eric; Dynowski, Krzysztof; Wilk, Krzysztof; Li, Yulan; Mathur, Vandana; Warsi, Qurratul Ann; Wagman, Rachel B; Johnson, Neil P. (2022). Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).. Lancet (London, England), 399(10343), 2267-2279. https://doi.org/10.1016/S0140-6736(22)00622-5
MLA
Giudice, Linda C, et al. "Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).." Lancet (London, 2022. https://doi.org/10.1016/S0140-6736(22)00622-5
RethinkPeptides
RethinkPeptides Research Database. "Once daily oral relugolix combination therapy versus placebo..." RPEP-06142. Retrieved from https://rethinkpeptides.com/research/giudice-2022-once-daily-oral-relugolix
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.